Business

Biotech, pharma, and money in science

Medical syringe
Biotech

A Regeneron drug dominates eczema treatment. With new data, a small biotech believes it can compete

By Adam Feuerstein

Haven
Business

What’s in a name? For the newly christened Haven, maybe another legal fight

By Casey Ross and Kate Sheridan

Overdrove the headlights
Biotech

‘We overdrove our headlights’: After his biotech startup fails, a CEO reflects on what went wrong

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Harvard
In the Lab

Hedge fund investing $100 million in Harvard drug research

By Jonathan Saltzman — Boston Globe

Theranos
Business

Documentarian Alex Gibney has taken on Enron, Scientology — and now Theranos

By Rebecca Robbins

Hospital Cloud illo
Hospitals

As tech giants compete for contracts, hospitals shift their data to the cloud

By Casey Ross

DNA testing kit - 23andMe
Business

23andMe will tell you how your DNA affects your diabetes risk. Will it be useful?

By Rebecca Robbins

Fenway Park
Politics

How do you improve Medicare? Maybe you watch Major League Baseball

By Nicholas Florko

Elizabeth Holmes - PROMO for DOC
Business

Review: In ‘The Inventor,’ you can’t know Elizabeth Holmes’s secrets. And yet you can’t turn away

By Damian Garde

Vials
Pharmalot

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

By Ed Silverman

Earth's City Lights at Night
The Pharmalot View

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

By Ed Silverman

Atul Gawande Innovation
Business

The Atul Gawande health care company finally has a name: Haven

By Casey Ross

Scott Robinson
Biotech

It costs $4,600 a month to rent a lab bench here. For startups, it’s the place to be

By Jonathan Saltzman — Boston Globe

Gottlieb vote
The Pharmalot View

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

By Ed Silverman

Purdue Pharma headquarters
Business

If Purdue Pharma declares bankruptcy, what would it mean for lawsuits against the opioid manufacturer?

By Andrew Joseph

Danielle D. Duplin
Business

Startups focused on aging have a home in new Kendall Square incubator

By Robert Weisman — Boston Globe

Blood samples stock
Biotech

Guardant’s blood test might replace biopsies for some lung cancer patients, study says

By Matthew Herper

D.C. Insight IMAGE
Politics

Webinar: Is the new Congress ready to lower drug costs?

By Lev Facher and Nicholas Florko

Digital health
Business

Biotech, yes, but how can Massachusetts become a digital health hub?

By Jonathan Saltzman — Boston Globe

Michael Cohen
Politics

For Novartis, the Michael Cohen affair just won’t stay dead

By Matthew Herper

Afrezza
Adam's Take

Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales

By Adam Feuerstein

Pharma CEO photo illustration
Politics

A letter from Executive Editor Rick Berke: All eyes on today’s drug pricing hearing

By Rick Berke

Zach Weinberg
Health

Can Roche’s little tech startup help the FDA change clinical trials?

By Matthew Herper

John Kapoor
Business

Insys’s scheme to deceive insurance companies detailed

By Maria Cramer — Boston Globe

Business

Judge rules former Optum exec can keep working at Atul Gawande’s new health venture, for now

By Kate Sheridan

The Sackler Wing
Business

Intensely private, deeply invested: Richard Sackler’s role in promoting OxyContin emerges in court documents

By Andrew Joseph

Jack Stoddard
Business

Unsealed testimony reveals a goal of Atul Gawande venture: ‘Make health insurance intelligible’

By Kate Sheridan

Kendall Square 1987
Biotech

Developers are scrambling for the next Kendall Square. Where will it be?

By Tim Logan

Amazon in the clouds
Business

Artificial intelligence can help clinicians, Amazon’s AI leader says. ‘But we need to ground that in truth’

By Casey Ross

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy